Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Arbutus Biopharma Corp ABUS

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company. The Company is leveraging its virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV) infection. Its HBV product pipeline includes Imdusiran and AB-101. Imdusiran is its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic product candidate. AB-101 is an oral PD-L1 inhibitor that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for.


NDAQ:ABUS - Post by User

Bullboard Posts
Comment by david77on May 01, 2007 7:44pm
467 Views
Post# 12707843

RE: 1 for 2 r/s from IEX shares

RE: 1 for 2 r/s from IEX sharesThis stock resumes retail trade on Friday after Tek shares are issued, Thurs at the earliest... Brokerages receive them and then convert them into your account.. You can't trade iex shares. Look for crazy share price swings on low volume till then. MM's... This is what I gather from the info. provided It looks like a 3for2 reverse split. Could be wrong? Don't know where the new inex will trade, if at all? It will take 3-10 Business days for the TKM shares to appear in your account. Your Broker will do the work automatically for you if your physical or electronic shares are with him. If you physically have the share certificates with you & not your broker then you have to do all the work. INEX had mailed a letter to all the registered IEX holder's or their agents or their broker's. BTW , Who is your Broker ??? He should be atleast aware of the spin-off..even if the account is not updated yet.It might show IEX for a week or so before it starts showing TKM & gets automatically updated. TJTHEMAN. NEWS RELEASE INEX has mailed a letter of transmittal to all registered INEX shareholders which will provide for the exchange of currently outstanding INEX common shares for shares of Tekmira. INEX shareholders are required to deposit with Tekmira's share transfer agent the certificate representing their current holdings of INEX shares and the letter of transmittal, properly completed and signed, in order to obtain common shares of Tekmira and INEX. One Tekmira common share will be issued for each post-consolidation INEX common share. As part of the spin-out, INEX common shares were consolidated on the basis of two current common shares for one new common share. Immediately before the spin-out of Tekmira, INEX common shares were consolidated on the basis of two current common shares for one new common share. INEX shareholders, as of the close of business on April 30, 2007, will own 100% of the new common shares of Tekmira and 20% of the equity of INEX. Effective May 1, 2007, the new common shares of INEX are de-listed from trading on the TSX. INEX will be seeking new opportunities outside the pharmaceutical industry under new management.
Bullboard Posts